Abstract 1748P
Background
Obesity has been recognised as one of the main risk factors for non- communicable diseases including cancer. WHO European report suggests that obesity affects 30% of children in Europe. Unhealthy diet is one of the most important determinants of childhood obesity, a condition that has become very prevalent in the south of Europe. Consumption of sugar-sweetened beverages (SSBs) influence childhood obesity and food advertisement is one of the strongest determinants of SSB consumption.
Methods
A multidisciplinary panel of clinicians from the South of Europe (Cyprus, Greece, Italy, Malta, Spain and Portugal) critically reviewed the available legislation and recommendations on SSB advertisements, in native language. The website of relevant national societies (Cardiovascular, Diabetic, Oncology, Paediatric and Stroke) was reviewed. Herein we present the recommendations from Oncology national societies.
Results
The countries in study have national legislations on SSB advertisements following EU directives with Spain having the most comprehensive regulatory framework. None of the oncology societies had recommendations on SSB consumption from children. The Spanish oncology society (SEOM) recognised obesity as risk factor for developing cancer and a close collaboration with the Spanish Association for the study of obesity is suggested. The Portuguese Society of Oncology (SPO) provides general guidance on the role of food and nutrition in cancer development. In Greece and Cyprus sporadic publications from the oncology society (HeSMO) on the preventive role of diet was noticed with no concrete guidance. Italian Oncology society (AIOM) has published on the role of nutritional support for cancer patients but the preventive role of healthy diet on childhood obesity is not available. European society of Medical Oncology links to IARC prevention strategies in the society website.
Conclusions
Recommendations on healthy diet to tackle childhood obesity, including SSB advertisement, from national medical societies in South Europe is fragmented. Oncology societies should join forces with other medical societies to increase awareness of childhood obesity and implement measures to address the phenomenon.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1912TiP - STELLAR-304: A randomized phase III study of zanzalintinib (XL092) and nivolumab in non-clear cell renal cell carcinoma (nccRCC)
Presenter: Sumanta Pal
Session: Poster session 23
2366P - Phase I-II study of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial)
Presenter: Daniel Castellano Gauna
Session: Poster session 23
2367P - A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Russells Pachynski
Session: Poster session 23
2368P - Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
Presenter: Patrizia Giannatempo
Session: Poster session 23
2369P - Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH)
Presenter: Bradley McGregor
Session: Poster session 23
2370P - Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Achille Bottiglieri
Session: Poster session 23
2371P - Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)
Presenter: Shilpa Gupta
Session: Poster session 23
2372P - Efficacy of a tailored approach with nivolumab (N) and nivolumab+ipilimumab (N+I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC
Presenter: Marc-Oliver Grimm
Session: Poster session 23
2373P - Outcomes by retrospective eligibility for maintenance therapy of patients (pts) with advanced urothelial carcinoma (UC): Post hoc analysis of KEYNOTE-361
Presenter: Ronac Mamtani
Session: Poster session 23
2374P - A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
Presenter: Petros Grivas
Session: Poster session 23